Editas Medicine
EDIT | NASDAQ
$1.87
-$0.30 (-13.82%)
At close: Nov 16, 2026, 4:00 PM ET
$1.90
+$0.03 (+1.60%)
After-hours:
Nov 16, 2026, 7:57 PM ET
-13.82%
(1D)No price chart data available for 1D timeframe.
Rating
55.5
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #179/1021 (Top 18%)
Key Statistics
Market Data
Market Cap $288.62M
1D Range
1.86 2.12
52W Range
1.67 3.75
Valuation (TTM)
PE -3.02
PB 3.41
EV/EBITDA -1.55
Valuation (NTM)
Forward PE N/A
Forward PEG 0.06
Price Target $5.50
Cash Flow
FCF Yield -38.3%
SBC Adj. FCF Yield -41.4%
SBC Impact -8.1%
Margins
Gross Margin 99.0%
Operating Margin -164.3%
FCF Margin -221.7%
Growth (CAGR)
Revenue 3Y | 5Y 26.5% |
15.3%
Dil EPS 3Y | 5Y 52.3% |
21.5%
FCF 3Y | 5Y 25.1% |
6.5%
Returns
ROA -32.9%
ROE -130.4%
ROIC -53.0%
Financial Health
Net Cash
$190.2M
Current Ratio 2.82
Interest Coverage 23.93
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene edi...
Sector Healthcare
Industry Biotechnology
Employees 87
IPO Date Feb 3, 2016
Website www.editasmedicine.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 9, 2026
EPS
-$0.15
Beat +19.05%
YoY:
+46.43% REV
$10.37M
Beat +132.42%
YoY:
+37.41%Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$5.50
Upside
+194.12%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove EDIT